June 17, 2025 — While much of the public has focused on the remarkable effects of GLP-1 agonists for many people living with obesity, an even more remarkable story has largely escaped notice. In March, FDA approved the first ever treatment for Prader-Willi syndrome. This drug, an extended-release form of diazoxide choline, is transforming the lives of families of […]
January 23, 2016 — The folks at Zafgen released a glimmer of hope for beloranib this week. On Wednesday, Zafgen announced that this investigational new drug met its two primary efficacy endpoints in the pivotal clinical trial for treating Prader-Willi syndrome (PWS). In December, that trial was halted after a second patient suffered a fatal blood clot in the […]
October 24, 2015 — Zafgen, a small biotech company “dedicated to the treatment of obesity,” is learning about the risks of their strategy of focusing on drug development for severe obesity. We’ve commented before that their focus is impressive and now it’s being tested. The pivotal randomized controlled trial (RCT) of the lead Zafgen obesity drug, beloranib, was halted after […]
